靶点- |
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer
The purpose of this study is to collect beginning information on whether intravenous (IV) administration of KRN5500 is safe and effective for treatment of neuropathic pain in patients with cancer.
100 项与 DARA Therapeutics, Inc. 相关的临床结果
0 项与 DARA Therapeutics, Inc. 相关的专利(医药)
100 项与 DARA Therapeutics, Inc. 相关的药物交易
100 项与 DARA Therapeutics, Inc. 相关的转化医学